This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ramos-Casals, M. Articles by Font, J. Search for Related Content PubMed PubMed Citation Articles by Ramos-Casals, M. Articles by Font, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Autoimmune Diseases Social Bookmarking                         What's this?

Mycophenolate mofetil in patients with hepatitis C virus infection

Department of Autoimmune Diseases, Institut d'lnvestigacions Biomèdiques August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Hospital Clinic, Barcelona, Spain

J. Font

Department of Autoimmune Diseases, Institut d'lnvestigacions Biomèdiques August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Hospital Clinic, Barcelona, Spain

Diagnosis and treatment of hepatitis C virus (HCV) -related autoimmune features has become a clinical challenge in HCV-infected patients, in whom chronic liver disease associated with severe autoimmune features may contribute to a very poor prognosis. Both antiviral and immunosuppressive therapies, either alone or in combination, seem likely to have a key role. Based on the experience of mycophenolate mofetil (MMF) use in HCV patients receiving organ transplantation, this new immunosuppressive agent might represent a safe and effective therapeutic option to treat HCV-related extrahepatic features. Recent data are available for the use of MMF in HCV patients with autoimmune manifestations, mainly for autoimmune cytopenias and vasculitic features. MMF may be used as monotherapy or in association with other drugs for cases of HCV-related autoimmune diseases refractory or intolerant to common immunosuppressive treatments, allowing the reduction of the drug dosage and avoiding serious side effects. Lupus (2005) 14, s64-s72.

Key Words: cryoglobulinemia • extrahepatic manifestations • hepatitic C virus • lymphoma • mycophenolate mofetil

Lupus, Vol. 14, No. 1 suppl, s64-s72 (2005)
DOI: 10.1177/096120330501400114


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?